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INTRODUCTION
Sibutramine, an anti-obesity drug, is a centrally acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines (Heal et al., 1998) . Sibutramine has been reported to increase cardiovascular disease potential (James et al., 2010) and has been withdrawn from the market in the United States, the European Union, and the Republic of Korea in 2010. Despite the offi cial ban of sibutramine, illicit products containing sibutramine are available in many countries, possibly resulting in signifi cant toxicities and even mortality (Muller et al., 2009; Tang et al., 2011; Heo and Kang, 2013) . The Sibutramine Cardiovascular and Diabetes Outcome Study (SCOUT) showed that long-term treatment (for 5 years) with sibutramine (10-15 mg/day) exposed subjects with preexisting cardiovascular disease to a signifi cantly increased risk for nonfatal myocardial infarction and nonfatal stroke, but not cardiovascular death or all-cause mortality (James et al., 2010) . However, QT prolongation, a prolonged interval from the beginning of the QRS complex to the end of the T wave of an electrocardiogram (ECG), an arrhythmia-associated effect induced by sibutramine is not well elucidated yet. In this study, we evaluated the cardiovascular safety of sibutramine with in vitro and in vivo models, which included human ether-a-gogo-related gene (hERG) assessment using whole-cell patch clamp electrophysiology techniques, action potential duration (APD) assessment using Purkinje fi bers, and a telemetry study in freely moving animals (beagle dogs).
MATERIALS AND METHODS

Animals and reagents
All animal procedures were approved by the committee on laboratory animal use (06141MFDS471) and performed in Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facilities conforming to the guidelines for care and use of laboratory animals provided by the Korean Ministry of Food and Drug Safety. Animals were housed in a temperature-controlled room at 22 ± 2°C with a
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Sibutramine is an anorectic that has been banned since 2010 due to cardiovascular safety issues. However, counterfeit drugs or slimming products that include sibutramine are still available in the market. It has been reported that illegal sibutramine-contained pharmaceutical products induce cardiovascular crisis. However, the mechanism underlying sibutramine-induced cardiovascular adverse effect has not been fully evaluated yet. In this study, we performed cardiovascular safety pharmacology studies of sibutramine systemically using by hERG channel inhibition, action potential duration, and telemetry assays. Sibutramine inhibited hERG channel current of HEK293 cells with an IC 50 of 3.92 μM in patch clamp assay and increased the heart rate and blood pressure (76 ∆bpm in heart rate and 51 ∆mmHg in blood pressure) in beagle dogs at a dose of 30 mg/kg (per oral), while it shortened action potential duration (at 10 μM and 30 μM, resulted in 15% and 29% decreases in APD 50 , and 9% and 17% decreases in APD 90 , respectively) in the Purkinje fi bers of rabbits and had no effects on the QTc interval in beagle dogs. These results suggest that sibutramine has a considerable adverse effect on the cardiovascular system and may contribute to accurate drug safety regulation. 12 h light/dark cycle (light on 0800 to 2000) and were given a solid diet and tap water ad libitum. All reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specifi ed. hERG assay HEK-293 cells (CRL-1573, ATCC) were transfected with hERG cDNA (GenBank U04270, donated from the Department of Physiology, Seoul National University, Republic of Korea) with GFP cDNA in pcDNA3.1/Zeo plasmids using lipofectamine. hERG currents were recorded using a wholecell patch clamp. Recording was performed with the Axopatch 200B amplifi er and Digidata 1322A converter (Axon Instruments, USA). Recording electrodes were pulled from borosilicate glass with fi lament (GC150 TF-7.5; Clark Electromedical Instruments, UK) on a micropuller (Narishige, Japan). The internal solution contained 130 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 5 mM MgATP, and 10 mM HEPES adjusted to pH 7.2. The extracellular solution was a normal tyrode solution adjusted to pH 7.4 that contained 143 mM NaCl, 5.4 mM KCl, 5.0 mM HEPES, 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , 16.6 mM glucose, and 1.8 mM CaCl 2 . The voltage step protocol (see Supplementary Fig. 1 ) was as follows: holding at -80 mV (resting potential), followed by an increase from -60 mV to +40 mV via 10-mV increments (step pulse, 0.1 Hz), and a stepdown to -60 mV. To assess the inhibitory effect of sibutramine (sibutramine·HCl, 99.72%; LKT Laboratories, Shenzhen, China) on the hERG channel current, we measured the tail current by a single pulse protocol (-80 mV potential holding step through a 2-s +20 mV depolarization step and a 3-s -60 mV repolarization step) from visually identifi ed GFP-positive cells (about 60% of transfection effi ciency) under a fl uorescence microscope (Axovision, Carl zeiss, Germany). Data from samples (n=3) were collected and analyzed with the Notocord rogram (NOTOCORD Inc., France).
APD assay
New Zealand white rabbits (male, 1.7-2.0 kg, Laboratory animal resources division, National Institute of Food and Drug Safety Evaluation) were sacrifi ced and Purkinje fi bers of the left ventricle were placed in the normal tyrode solution and equilibrated for 2 h (O 2 saturation at 37°C) at 1 Hz, 2 ms (1.5 times the threshold stimulation value). A microelectrode (20 MΩ, 3 M KCl fi lling) was inserted and the membrane potential was adjusted to -80 mV. Stimulus (1.3-2V, 2 ms, 1 Hz) was supplied at 37 ± 1°C through fl ow. After equilibration for 1 h, action potential changes induced by sibutramine treatment (20 min) were measured and analyzed with the Notocord program. Action potential duration upon 50% repolarization (APD 50 ), action potential duration upon 90% repolarization (APD 90 ), resting membrane potential (RMP), total amplitude (TA), and Vmax were measured 30 times immediately before treatment with a higher concentration of sibutramine, as described previously (Seop Kim et al., 2006) .
Telemetry
Canis familiaris (beagle dogs, n=4, male, ~9.0 kg, Laboratory animal resources division, National Institute of Food and Drug Safety Evaluation) underwent surgery and implantation of a transmitter (TL11M2-70-CT type, Data Science International, USA) as described previously (Kim et al., 2005) . The telemetry study followed a crossover design in which four male beagle dogs were given a single oral dose of either the vehicle or one of four dose levels of sibutramine: 1, 3, 10, or 30 mg/kg. A washout period of at least 72 h was maintained between each dose and for all animals. The effects of sibutramine administration on blood pressure, heart rate, and QT interval were measured for 10 min at 1-h intervals over a 24-h period with the DataQuest software package (Data Sciences International, MN, USA) in conscious beagle dogs.
Statistics
Statistical analyses were performed using SigmaStat 3.1 software (Systat Software, Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Dunnett's test or repeated measures ANOVA followed by Bonferroni's test were used for multigroup comparisons.
RESULTS
hERG assay
The hERG encodes the pore-forming protein KCNH2, which is thought to represent the α-subunits of the human potassium channels responsible for IKr. The most common mechanism of QT prolongation is the blockage of this ion channel. The concentration-dependent inhibition of IKr in hERG-transfected HEK293 cells by sibutramine is shown in Fig. 1 . The hERG current was inhibited by 25.26 ±1.71%, 52.62 ± 10.92%, and 96.51 ± 1.38% at 1 μM, 3 μM, and 10 μM, respectively, with an IC 50 of 3.92 μM (Hillslope: 1.9768). Biomol Ther 23(4), 386-389 (2015) http://dx.doi.org/10.4062/biomolther.2015.033
APD assay
In addition to the hERG assay, we performed the APD assay, which can elucidate cellular mechanisms affecting repolarization. In the left ventricular Purkinje fi bers of rabbit, sibutramine decreased APD 50 and APD 90 at 10 μM and 30 μM without infl uencing the total amplitude, resting membrane potential, and V max (Table 1 ).
Telemetry
Telemetry assay was performed in freely moving animals (conscious dogs) to determine whether ventricular repolarization or associated arrhythmias occurred due to integrated effects on the full complement of ion channels and cell types. Table 2 shows the baseline cardiovascular parameters in each dog. Following oral administration of sibutramine-fi lled gelatin capsules to conscious dogs followed by 24-h observation, there were no signifi cant or biologically relevant changes in lead II ECG variables (RR, PR, QRS, QT, QTcF [corrected QT interval using Fridericia's formula; QT/RR 0.33 ]). In contrast, the heart rate and mean blood pressure were signifi cantly higher after administration of sibutramine (30 mg/kg) in comparison with that in the control group. In particular, the maximal effects of sibutramine on heart rate (76 ∆bpm) and blood pressure (51 ∆mmHg) were observed at 9 h and 6 h after administration, respectively (Fig. 2) .
DISCUSSION
Sibutramine was reported to induce mania, panic attacks, and psychosis (Perrio et al., 2007) . Furthermore, sibutramine was withdrawn from the U.S market and also from the EU and the Republic of Korea due to the risk of serious cardiovascular events. Recent studies reported that sibutramine present in counterfeit drugs and dietary supplements contributes to a safety issue; however, the association of QT prolongation with sibutramine is not clearly understood yet. We evaluated the possible mechanism underlying sibutramine-induced cardiovascular adverse effect. We demonstrated that sibutramine inhibited hERG potassium channels in an in vitro test system, while the APD assay in Purkinje fi bers of rabbit showed that sibutramine induced a decrease in APD 50 and APD 90 . These results are consistent with previous report that showed APD shortening induced by sibutramine in guinea pig papillary muscle (Kim et al., 2008) . It is not surprised because a cardiac action potential is composed of different phases that are produced by the currents of Na + , Ca 2+ , and K + . We presumed that sibutramine has a weak QT prolongation and APD shortening effect due to mixed ion channel effects. In addition, the in vivo telemetry experiments revealed that an acute sibutramine administration may not have effects on QT prolongation. However, sibutramine, at 30 mg/kg, increased the heart rate and mean blood pressure in beagle dogs. Sibutramine is known to have a peripheral sympathomimetic effect, consequently this may affect hemodynamic parameters. In fact, a shortened APD may contribute to the changes of heart rate and blood pressure in beagle dogs, because APD and the refractory period decrease is essential for increase in the heart rate. Additional in vivo models that are designed to study possible risk factors (e.g. chronic administration and electrolyte imbalance) could be considered that might better reveal the basis of QT prolongation. In summary, our results suggest that sibutra- www.biomolther.org mine is associated with cardiovascular risks reported previously (Scheen, 2010) , even though we could not establish a causal relationship between QT prolongation and sibutramine. Furthermore, these results may contribute to the regulatory response to sibutramine safety issues. 
